You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bevacizumab

Showing 26 - 50 of 3,098
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • Tas-102(Suyuan) combined with bevacizumab
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)

Recruiting
  • Colorectal Cancer Metastatic
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 3, 2023

Head and Neck Squamous Cell Carcinoma Trial (Carrilizumab, bevacizumab,capecitabine)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Carrilizumab, bevacizumab,capecitabine
  • (no location specified)
Jul 20, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Glioblastoma Trial (Tislelizumab and Bevacizumab)

Not yet recruiting
  • Glioblastoma
  • Tislelizumab and Bevacizumab
  • (no location specified)
Apr 12, 2023

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • (no location specified)
Sep 11, 2023

Metastatic Colorectal Cancer Trial in Madison (Liposomal irinotecan, TAS102, Bevacizumab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Liposomal irinotecan
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
May 2, 2023

Colorectal Cancer Trial in Shanghai (FOLFIRI+Bevacizumab)

Recruiting
  • Colorectal Cancer
  • Shanghai, Pudong, China
    Affiliated Cancer Hospital of Fudan University
Jul 24, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 4, 2023

Trifluridine/Tipiracil Plus Bevacizumab Versus

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
May 11, 2023

Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)

Not yet recruiting
  • Advanced HCC
  • Other Solid Tumors
  • Shanghai, China
    Zhongshan Hospital
Jun 13, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Bevacizumab combined with Sintilimab, Transcatheter arterial chemoembolization)

Recruiting
  • Hepatocellular Carcinoma
  • Bevacizumab combined with Sintilimab
  • Transcatheter arterial chemoembolization
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 14, 2023

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Thyroid Carcinoma, Surgery Trial in Groningen (Bevacizumab-IRDye800CW)

Enrolling by invitation
  • Thyroid Carcinoma
  • Surgery
  • Groningen, Netherlands
    University Medical Center Groningen
Oct 18, 2023

Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023

Hepatocellular Carcinoma Trial in Tianjin (HAIC, Adebrelimab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • HAIC
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
Jul 27, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

Recruiting
  • Breast Cancer With Brain Metastases
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023

Hepatocellular Carcinoma by BCLC Stage Trial in Guangzhou (Bevacizumab Biosimilar QL 1101)

Not yet recruiting
  • Hepatocellular Carcinoma by BCLC Stage
  • Bevacizumab Biosimilar QL 1101
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 20, 2023

Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Fuzuloparib Combination with Bevacizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Cente
Apr 14, 2023

Pleural Mesothelioma Trial in Guangzhou (Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin)

Not yet recruiting
  • Pleural Mesothelioma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 3, 2023

NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage II
  • +3 more
  • Serplulimab combined with bevacizumab and first-line chemotherapy
  • Guangzhou, Guangdong, China
    Likun Chen
Apr 10, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 16, 2023